Aura Biosciences Inc Dossier
Qualitative Analysis
Business overview
Aura Biosciences, Inc. is a clinical-stage biotechnology company pioneering a novel class of precision oncology therapies designed to target and destroy cancer cells selectively while preserving organ function and activating the immune system. The company's proprietary platform leverages virus-like drug conjugates (VDCs) to target solid tumors, with an initial focus on ocular and urologic oncology. Its lead product candidate, belzupacap sarotalocan (bel-sar, AU-011), is in late-stage clinical development for the first-line treatment of early-stage choroidal melanoma and is also being evaluated in non-muscle invasive bladder cancer (NMIBC).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead virus-like drug conjugate (VDC) candidate through the global Phase 3 CoMpass trial to establish a frontline, vision-preserving alternative to traditional radiation therapy.
Expected impact: Potential to achieve the first FDA-approved frontline therapy for early choroidal melanoma, validating the proprietary VDC platform.
Evaluating bel-sar in a Phase 1b/2 clinical trial for non-muscle-invasive bladder cancer (NMIBC) to expand the therapeutic footprint into non-ocular solid tumors.
Expected impact: Establishes clinical proof-of-concept in urologic oncology and expands the addressable market for the VDC platform.
Conducting proof-of-concept trials for bel-sar in adjacent ocular indications, including metastases to the choroid (Phase 2) and ocular surface cancers (Phase 1).
Expected impact: Broadens the ocular oncology pipeline to address high unmet medical needs with no currently approved therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations